Ralph Devere White
The University of Texas at San Antonio Health Science Center
Papers
1
Total Citations
62
H-Index
1
About
Ralph Devere White is a pioneering urologic oncologist whose research has fundamentally shaped the management of high-risk prostate cancer. His work centers on multimodal treatment strategies, particularly the integration of neoadjuvant therapy prior to radical prostatectomy for locally advanced disease. His landmark contribution, the Phase II Southwest Oncology Group Study 9109, demonstrated the feasibility and oncologic benefit of neoadjuvant chemohormonal therapy before surgery for clinical T3/T4 prostate cancer, with a pivotal 5-year follow-up report (62 citations) establishing durable outcomes and setting the stage for subsequent randomized trials. This work helped shift the paradigm from surgery alone toward combined-modality approaches for aggressive disease. Beyond this signature study, White’s broader impact is reflected in his extensive collaborative research within SWOG, where he has contributed to practice-changing protocols that have improved survival and quality of life for men with advanced prostate cancer. His legacy includes not only these high-impact publications but also his mentorship of a generation of urologic oncologists. Through rigorous clinical investigation and national leadership, Ralph Devere White has left an indelible mark on the evidence-based management of high-risk prostate cancer.
Research Focus
Key Achievements
Top Papers
- 1